The latest approved anti-obesity therapeutic is liraglutide that is a glucagon-like peptide-1 (GLP-1) analog, or named GLP-1 receptor agonist (GLP-1RA). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.